HGH Fragment 176-191
HGH Fragment 176-191 is a growth hormone fragment with animal data only. No human trial tested it.
Checked by the PU Research editorial team — evidence-graded against primary sources. Last check: 23 July 2026. Sources: 2. Who checks this
01Identity & Classification
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone. It covers residues 176 to 191.
02Mechanism: How It Works
The proposed mechanism is lipolysis, plus an inhibition of lipogenesis, through a beta-3 adrenergic pathway.
Preclinical reports describe no increase in IGF-1 and no activation of the growth hormone receptor.
03Research Findings
Evidence tier: preclinical only.
The unmodified native fragment never advanced to a formal human trial.
Identity warning. The developed and stabilized analog is AOD-9604. The two molecules are related. They are not identical. A claim about one does not transfer to the other.
04Reported Dosing & Delivery
No high-authority human dosing exists. Only non-clinical community reports exist. This site does not publish them.
Not approved for human use.
05Pharmacokinetics & Timing
Human pharmacokinetics are not well characterized.
06Interactions & Combinations
No high-authority source documents an interaction.
Compare with AOD-9604.
07Safety & Contraindications
No clinical human safety data exist. Preclinical reports describe the fragment as glucose-neutral.
08Monitoring & Biomarkers
Glucose, in a research setting.
09Regulatory Status
No regulator approves it. The WADA 2026 Prohibited List names hGH 176-191 under S2.2.
See the WADA prohibited list status.
10Works Cited
- 01Heffernan M, et al. Endocrinology, 2001. View source →
- 02WADA 2026 Prohibited List, section S2.2. View source →
More in Metabolic & Body Composition
Open the Metabolic category →Semaglutide
Semaglutide is a GLP-1 receptor agonist. The FDA approves it for type 2 diabetes and for chronic weight management.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The FDA approved it on 13 May 2022.
Retatrutide
Retatrutide is an investigational triple receptor agonist. No regulator approves it. Phase 3 work continues.
Research use only. This is not medical advice.
PeptideUnlock gives education. Nothing here diagnoses a condition. Nothing here recommends a compound or a dose.
Most peptides on this site have no approval for human use in any country. Some carry documented harms. Several are prohibited in sport.
Regulatory status changes by country and by month. Check the current rule where you live. Speak to a licensed clinician before any health decision.